Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...

Eli Lilly's (NYSE:LLY) weight-loss drug Zepbound is now reportedly covered by Medicare for the treatment of obstructive sleep ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

Opens in a new tab or window The FDA approved tirzepatide (Zepbound) for adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity, the agency announced late Friday. Used along with ...

On Dec. 20, the FDA announced that the agency has approved Eli Lilly's Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The drug is to be ...

Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

On December 20, 2024, pharmaceutical company Eli Lilly announced that the FDA approved its first and only obstructive sleep apnea medication. Zepbound or Tirzepatide is an injectable drug that the ...

In another development, the US Food and Drug Administration (FDA) recently approved the first drug to treat obstructive sleep apnea. It’s a weight-loss drug called Zepbound (tirzepatide ...